Zydus Lifesciences announced that FDA has granted approval for its generic drug submission referenced by ANDA217758, potentially impacting the market share of the branded equivalent. The green light, effective as of May 15, 2026, sets the stage for the company to expand its portfolio and leverage additional revenue opportunities in the space.